Different Grades Of Meningioma Research Articles

Investigating The Expression of ER, PR, And Ki-67 In Different Grades of Meningioma

Introduction: Tumor grade is one of the significant factors in determining the prognosis of meningioma. Ki-67 is a marker expressed in the active phase of the cell cycle and indicates cell division and can be used as an auxiliary tool in determining the grade of meningioma. Steroid hormones are one of the factors that are effective in the pathogenesis of meningioma. This study evaluates the expression level of ER, PR, and ki-67 markers in different grades of meningioma.
 Materials and Methods: In a descriptive study, slides, and paraffin blocks of 80 meningioma patients who underwent surgery over 10 years at Besat Hospital, Hamedan, were extracted from the patient’s medical records and were evaluated in terms of the expression of ER markers, PR and ki-67 after immunohistochemical staining. Results: In meningioma grades 1, 2, and 3, mean PR expression was 17.33, 11.66, and zero (P=0.033), respectively, and mean Ki-67 expression was 0.67, 5.22, and 10.50, respectively ( P<0.001), and mean ER expression was zero in all three grades. There was an inverse and significant correlation between tumor grade and PR rate (p=0.04, r=-0.21). Conclusion: ki-67 expression can be used as an auxiliary method in meningioma grading, and more PR positivity indicates lower grades, and thus, better tumor prognosis.

Immunohistochemistry expression of stem cell markers SOX2, OCT4, CD133 in different grades of meningiomas and correlation with Ki 67 index

Immunohistochemistry expression of stem cell markers SOX2, OCT4, CD133 in different grades of meningiomas and correlation with Ki 67 index

Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy.

BackgroundMeningioma arising from meninges is one among the various types of brain tumors. Others are, astrocytomas originating from astrocyte, oligodendrogliomas originating from oligodendrocyte, Ependymomas originating from ependymal cells and medulloblastomas originating from neurons. Current knowledge of molecular biology, genetics and epigenetics of meningioma is not sufficient. Therefore, In depth understanding of the mechanism of meningioma formation and progression is needed for its treatment and management. Grade I Grade I meningiomas are majorly classified as grade I, grade II and grade III. Meningioma can be indolent, slow growing or can be invasive and metastatic which can recurre. Grade I meningioma can be removed by surgery in comparison to invasive meningioma which may recurre with high propensity. This property of recurrence is responsible for high morbidity and mortality. Meningioma are majorly classified into three classes namely grade I, grade II, grade III. Protein biomarkers are considered as promising candidates for the diagnosis of meningioma.StudyVarious studies done on differential expression of proteins have shown increased expression of EGFR, NEK9, EPS812, CKAP4, SET and STAT2, in all the three grades of meningioma. Additionally, some proteins like HK2 are overexpressed in grade II and grade III meningioma than in grade I meningioma. Protein Markers, found on extracellular vesicles of different grades of meningioma can serve the same purpose. A test done on a sample of any kind of body fluid like blood, tear, saliva, urine etc. for recognizing the circulating cancer cells or DNA and extracellular vesicles released from them to help detecting the early stage of cancer is known as liquid biopsy. Solid biopsy has several limitations as compared to liquid biopsy. This is because the samples can be easily collected and studied in case of liquid biopsy. Exosomes are related with liquid biopsy and hence provide platform for better diagnosis, prognosis and treatment of any type of cancer including meningioma. Exosomal tetraspanin are important example of exosomal biomarkers. The tetraspanin network is a molecular scaffold which connects various proteins for signal transduction.ConclusionThis study tells about the utility of proper knowledge of extracellular vesicle proteins and their profiles in different grades, which can help in better understanding of pathogenesis, diagnosis, prognosis and treatment of meningioma. In Addition to use of these proteins as biomarkers, role of exosomes in currently available therapeutic approaches has been discussed.

Overexpression of Hepatocyte growth factor and its soluble receptor (s-cMet) in the serum of patients with different grades of meningioma

ObjectivesMeningiomas are the most common primary intracranial tumor. Hepatocyte growth factor (HGF) and its receptor, cMet, were shown to be involved in meningioma. This study was aimed to determine the concentration of HGF and soluble cMet (s-cMet) in the serum of patients with different grades of meningioma. MethodsNinety serum samples from different grades of meningioma patients (42 cases of grade I, 28 grade II, 20 grade III) and 51 controls were included in this study. The serum total protein concentration (TPC) was measured by a Bio-Rad protein assay and serum concentration of HGF and s-cMet by enzyme linked immunosorbent assay (ELISA). ResultsNo significant change in the serum TPC of patients was seen as compared to controls. We also showed that serum HGF and s-cMet concentration in meningioma patients was higher than in controls. The results showed that starting from grades I to III meningioma, a significant increase in HGF and s-cMet serum concentration was observed (HGF; 380 ± 57.69, 430.27 ± 48.72, 596.36 ± 104.49 pg/ml, respectively, as compared to controls which was 327.72 ± 49.68 pg/ml and for s-cMet was 274.45 ± 45.05, 314.81 ± 38.71, 433.54 ± 51.81 ng/ml, respectively, as compared to controls which was 213.72 ± 29.13 ng/ml). The results showed that a high concentration of HGF and s-cMet is associated with advanced grades of meningioma. ConclusionIt is concluded that HGF and s-cMet serum levels increased in meningioma patients and their concentration was significantly higher in more advanced grades of the disease. It is also suggested that HGF/s-cMet might be involved in the progression of meningioma.

Endocan serum levels in patients with low- and high-grade meningiomas: does this biomarker have an indicative role?

BackgroundMeningiomas are one of the most common tumors of the brain and central nervous system. The key role of endocan in predicting tumor growth and prognosis has been shown for several types of cancers; however, this role in meningiomas has not been evaluated. In the current study, we investigated the relationship between endocan serum levels with low- and high-grade meningiomas.ResultsThe serum level of endocan in the group with meningiomas was 283.34 (242.09-358.70) pg/ml and in the control group was 250.29 (207.56-329.71) pg/ml respectively (P = 0.172). Afterwards, patients were divided into three different groups (grades I, II, and III) and compared to the control. The level of endocan in the group with grade I of meningioma showed no significant difference compared to control individuals (P = 0.86). When patients with grade II and grade III compared with the control group, endocan serum levels were statistically significant (P = 0.002, P < 0.001 respectively). Moreover, our findings showed that the different grades of meningiomas were statistically significant compared to each other (P < 0.001) regarding endocan serum levels, meaning that the higher the grade, the higher the endocan serum levels.ConclusionOur findings revealed that higher grades of meningioma had higher endocan serum levels, however, the role of endocan in pathogenesis or progression of this type of tumor requiring further exclusively assessment.

Immunohistochemical expression of matrix metalloproteinase -9 in invasive meningioma

Background: Meningioma is a common intracranial tumor arising from the meningothelial (arachnoid) cells. Meningiomas are divided into 15 histological subtypes and three grades, including benign (grade I), atypical (grade II) and anaplastic (grade III). It is important to correctly decide whether a meningioma isbrain-invasive or not. Tumor invasion can be described as a stepwise process involving the degradation of the extracellular matrix (ECM), tumor cell adhesion to resident cells or components, increased proliferation, and cell migration into new intracellular/ECM space. It is believed that expression of Matrix metalloproteinases (MMPs) can be related with this process, especially the matrix metalloproteinase-9 (MMP9). Objectives: Investigation of matrix metalloproteinase-9 expression in different grades of meningioma and correlate this expression with brain invasion. Patients and methods: Matrix metalloproteinase-9 immunostaining was studied in 50 specimens of meningioma using avidin-biotin peroxidase method. Results: The percentage of brain invasive was 5% as regard to MMP9 score 1 ,5% as regard MMP9 score 2,20% as regard MMP9 score 3,70% as regard MMP9 score 4. A significant positive correlation was found between MMP9score and brain invasion (p < 0.001). Conclusion: Increased MMP9 expression is correlated with brain invasion.

Lack of Correlation Between Immunohistochemical Expression of SPARC and Invasion in Different Grades of Meningiomas.

Grade I meningiomas are generally benign and non-invasive whereas Grade II (atypical) and Grade III (malignant) meningiomas tend to be invasive with a high risk of recurrence. SPARC, secreted protein, acidic and rich in cysteine, is a multifunctional glycoprotein which has been proposed to be a potential diagnostic marker of invasive meningiomas. There has been increased reporting of atypical meningiomas since the current World Health Organization (WHO) included brain invasion as a grading criterion for classification of these particular meningiomas. The aim of this study was to re-evaluate any correlation between immunohistochemical expression of SPARC in 34 meningiomas of various grades using the current classification (2016). We had previously classified these cases using the 2002 WHO criteria. There is no correlation between expression of SPARC and invasion in different grades of meningioma. SPARC does not appear to be a good predictor of invasion in meningiomas.

Value of MRI Radiomics Based on Enhanced T1WI Images in Prediction of Meningiomas Grade

Different grades of meningiomas require different treatment strategies and have a different prognosis; thus, the noninvasive classification of meningiomas before surgery is of great importance. The purpose of this study was to explore the application value of magnetic resonance imaging (MRI) radiomics based on enhanced-T1-weighted (T1WI) images in the prediction of meningiomas grade. A total of 98 patients with meningiomas who were confirmed by surgical pathology and underwent preoperative routine MRI between January 2017 and December 2019 were analyzed. There were 82 cases of low-grade meningiomas (WHO grade I) and 16 cases of high-grade meningiomas (7 cases of WHO grade II and 9 cases of WHO grade III). These patients were randomly divided into a training group and test group according to 7:3 ratio. The lesions were manually delineated using ITK-SNAP software, and radiomics analysis were performed using the Analysis Kit (AK) software. A total of 396 tumor texture features were extracted. Subsequently, the LASSO algorithm was used to reduce the feature dimensions. Next, a prediction model was constructed using the Logistic Regression method and receiver operator characteristic was used to evaluate the prediction performance of the model. A radiomics prediction model was constructed based on the selected nine characteristic parameters, which performed well in predicting the meningiomas grade. The accuracy rates in the training group and the test group were respectively 94.3% and 92.9%, the sensitivities were respectively 94.8%, and 91.7%, the specificities were respectively 91.7% and 100%, and the area under the curve values were respectively 0.958 and 0.948. The MRI radiomics method based on enhanced-T1WI images has a good predictive effect on the classification of meningiomas and can provide a basis for planning clinical treatment protocols.

Evaluation of galectin 3 and phosphohistone H3 immunoexpression as prognostic markers for meningioma

Background Meningiomas are not uncommon tumors of central nervous system. Their incidence is ∼25.6% of intracranial tumors in Egypt. Usually, meningiomas do not invade the surrounding brain structures. However, some variants acquire invasive and infiltrative nature. Galectin 3 is found in many cell types. It is expressed in various cellular processes such as cell growth, apoptosis, adhesion, chemotaxis, and differentiation. It is also expressed in different malignancies. Usually it is correlated with tumor progression. Histone H3 phosphorylation is specific to mitosis in premitosis stage and late G2 phase. Phosphohistone H3 (PHH3) immunohistochemistry is significant for mitosis detection in malignancy, and its expression is usually linked to worse prognosis. Aim To study immunohistochemical expression of galectin 3 and PHH3 with other clinicopathological parameters of different grades of meningioma. Results Galectin 3 expressions were related significantly with large tumor size, advancing grade, and brain invasion. PHH3 high proliferative score was also significantly associated with large tumor size, advancing grade, presence of postoperative recurrence, and brain invasion. Conclusion PHH3 is involved in tumor recurrence. Both PHH3 and galectin 3 are involved in brain invasion. These molecules can be used as important potential therapeutic targets and predictors for meningioma prognosis.

Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma

ObjectiveMeningiomas are common primary brain tumors that constitute about 13% of all intracranial tumors. Matrix metalloproteinase-9 (MMP-9) is able to degrade the extracellular matrix and basement membrane leading to cancer cell invasion and metastasis. MMPs are specifically inhibited by a family of small extracellular proteins known as the tissue inhibitors of metalloproteinases (TIMPs). The objective of this project was to evaluate serum concentration of TIMP-1 and TIMP-2 in patients with different grades of meningioma. Patients and MethodsNinety samples from different stages of patients with meningitis (42 cases of grade I, 28 grade II, 20 grade III) and 51 samples from normal healthy were included in this study. Total protein concentration (TPC) and the level TIMP-1 and TIMP-2 serum were determined by Bio-Rad protein assay based on the Bradford dye procedure and enzyme-linked immunosorbent assay (ELISA), respectively. ResultsNo significant change in the TPC was seen in the serum of patients with meningioma when compared with normal controls. Results obtained demonstrated that all serum samples presented TIMP-1 and TIMP-2 expression, whereas, starting from grade I to III meningiomas, a significant decrease of TIMP-1 and TIMP-2 expression was observed as compared to controls. ConclusionThe results of this study show that a low expression of TIMP1 and TIMP2 is correlated with advanced stages of meningioma. It is also concluded that the detection of serum TIMP1 and TIMP2 may be useful in classifying different grades of meningioma.

Predictive value of p53 and ki67 in different grades of meningioma

Meningiomas are common tumors of the central nervous system that originate from the meningeal coverings of the brain and the spinal cord. Many factors are involved in tumor progression,one of the important factors is mutation of tumor suppressor gene p53. Ki-67 is considered to be the most reliable proliferative marker predicting tumor behavior.The aim of the present study is to evaluate the use ofimmunhistochemical expression of p53 and ki67 for predicting the grades of meningioma which are important in their prognosis.Sixty patients with different grades of meningioma were taken. Histological sections of the paraffin embedded tissues of these cases were be taken for H&amp;E staining for assessment of histological grade according to WHO grading system. Immunohistochemical staining of sections of the paraffin embedded tissues by using monoclonal antibody for P53 &amp; ki-67 were done. Correlation between tumor grades and immunhistochemical markers were done.The presences of mitosis,sheeting,prominent nucleoli,hypercellularity,pleomorphism,and the necrosis,except brain invasion,were correlated with tumor grades. The mean Ki-67 labeling index was significantly higher in meningiomas of WHO grade III than in those of grades I and II. Overexpression of p53 was found mainly in the atypical and malignant meningioma group. There is a good and positive correlation between Ki-67 and p53 expression.The Ki-67 proliferative marker and p53 are both presented highly in atypical and malignant meningioma,the routine use of them in predicting the behavior of meningiomas may be advocated based on the results of this study.

Global proteome and phosphoproteome analysis of meningiomas

Meningiomas are common brain tumours arising from meningeal tissue. Despite the majority of them displaying benign features, they can cause mild to severe morbidity. The current main therapeutic approach is complete tumour resection commonly with adjunct radiation therapy. However, tumour location can hamper complete resection and chemotherapies are ineffective. In this study we aim to elucidate dysregulated pathways in meningioma pathogenesis and identify novel molecular targets by deciphering the proteome and phosphoproteome of different grades of meningiomas. Tumour lysates were collected from grade I, II and III frozen meningioma specimens and three normal healthy human meninges. Phosphoprotein purification was performed using Qiagen® PhosphoProtein Purification Kit. Proteins were separated by SDS-PAGE followed by in-gel tryptic digestion. Extracted peptides were purified and analysed by electrospray ionization LC-MS/MS. Raw mass spectrometry files were analysed using MaxQuantTM. Expression data was validated by Western blot and functionally annotated using Ingenuity® Pathway Analysis (IPA®) and DAVID 6.8. We have quantified 3888 proteins and 3074 phosphoproteins across all grades of meningioma and normal meninges. Comparative analysis confirmed 181 proteins and 338 phosphoproteins to be commonly significantly upregulated (log2 fold-change≥1.5; p<0.05) among all grades vs. normal meninges. We have successfully validated the expression data of several upregulated proteins and phosphoproteins. Gene Ontology revealed biological processes including EFGR and VEGFR signalling to be enriched in the phosphoproteome. Grade-wise comparisons identified 667 proteins and 769 phosphoproteins to be differentially expressed (p<0.05) between grade III meningiomas compared to grade II and I. We have performed a comparative proteomic analysis across all meningioma grades and identified changes in proteomic profiles between these tumours and normal healthy meninges. We will use this data to define novel targets common to all grades and specific to a grade of meningioma for future therapies.

Histopathological Analysis and Correlation of Ki67 and Progesterone Receptor Status with WHO Grading In Meningiomas

Background: Meningiomas are slow growing tumors that are among the most common of CNS neoplasms and form the most common CNS tumor to be reported above 35 years of age. Materials &amp; Methods: This retrospective study was carried out in the Department of Pathology during the period of January2011 to May2013. A total of 50 cases were graded according to the WHO 2016 grading criteria. The biopsy specimens were fixed in 10% neutral buffered formalin, sections was stained with Hematoxylin &amp; Eosin. Immunohistochemistry was done with Progesterone receptor and Ki67 antibodies for selected cases. Results: The incidence of meningiomas was 33.11% with a female sex predilection and most common in the 5th decade. Transitional meningioma was the most common variant to occur. The incidence of WHO Grade I, Grade II and Grade III meningiomas were 88%, 4% and 8% respectively. Comparison of Ki67 LI and PR score in various grades of meningiomas were done. The average Ki67 LI and PR score were 1.1%, 10.25; 6%, 3; 16%, 0 in grade I, II and III meningiomas respectively. p value showed a statistically significant difference between different grades of meningiomas with respect to PR and Ki67 status. Spearman correlation showed a clearly significant inverse relationship between the two antibodies. Conclusion: The use of immunohistochemical markers aids in determining the aggressive nature of the tumor, its recurrence potential and can be used as prognostic markers.

The role of three-dimensional pseudo-continuous arterial spin labelling in grading and differentiating histological subgroups of meningiomas

To evaluate the usefulness of pseudo-continuous arterial spin labelling (pCASL) imaging in grading and differentiating histological subtypes of meningiomas. In this prospective study, conventional magnetic resonance imaging (MRI) with contrast-enhanced T1-weighted images and pCASL were acquired with a 3 T MRI system before surgery in 125 consecutive patients with suspected meningiomas. Finally, the perfusion parameters were collected from 84 grade I and 23 grade II meningiomas. On the pCASL perfusion map, the mean absolute cerebral blood flow (CBF) values from the meningioma (CBFtumour), peritumoural oedema (CBFPTO), white matter of contralateral centrum semi-ovale (CBFwm) and normal grey matter (CBFgm) were calculated. Additionally, the associations of these perfusion parameters with the value of ki-67 index were analysed. The CBFwm value correlated negatively with the largest diameter of the tumour, which limited its usage as a reference for ratio calculation. The CBFtumour values of grade II and grade I meningiomas did not differ significantly: 137.36±71.85 ml/min/100 g versus 123.58±135.80 ml/min/100 g (p=0.641). The CBFPTO value was higher for grade II meningioma as than for grade I meningiomas: 30.30±15.56 ml/min/100 g versus 22.33±9.87 ml/min/100 g (p=0.037). The CBFtumour value was highest in angiomatous meningioma and lowest in fibrous meningioma, thus enabling the differentiation of subtypes of meningioma. The CBFtumour value did not correlate with the ki-67 index of meningioma. The CBFPTO value, rather than the CBFtumour value, from pCASL imaging may serve as a key factor in distinguishing different grades of meningiomas. Moreover, angiomatous meningiomas and fibrous meningiomas can be identified by CBFtumour value.

Evaluation parameters between intra-voxel incoherent motion and diffusion-weighted imaging in grading and differentiating histological subtypes of meningioma: A prospective pilot study

PurposeTo prospectively evaluate the usage of intra-voxel incoherent motion (IVIM) magnetic resonance imaging (MRI) parameters in grading and differentiating histological subtypes of meningiomas and in comparing their ability with the traditional diffusion-weighted imaging (DWI) parameter (apparent diffusion coefficient, ADC). MethodsIn this prospective study, 102 participants underwent IVIM MRI and DWI. Traditional DWI and IVIM MRI were performed by using 2 b values (0, 1000s/mm2) and 12 b values (0–3500s/mm2), respectively. Finally, the values of ADC and IVIM parameters were collected from 72 Grade I and 11 Grade II meningiomas. ResultsThe mean ADC values of Grade II and Grade I meningiomas were 0.909±0.268×10−3mm2/s and 0.905±0.194×10−3mm2/s, respectively, p=0.967. The D values were lower in Grade II meningiomas than in Grade I meningiomas (0.459±0.072×10−3mm2/s vs. 0.524±0.030×10−3mm2/s, respectively, p=0.005). In ROC curves, the cut-off D value that separated Grade II meningiomas from Grade I meningiomas was 0.479×10−3mm2/s with a sensitivity of 90.9% and a specificity of 76.7%. The secretory and angiomatous meningiomas had higher IVIM parameters than the other subtypes (all p<0.05). D* was significantly lower in fibrous meningiomas than in other meningiomas (2.783±1.179×10−3mm2/s vs. 5.125±1.918×10−3mm2/s, p<0.001). D, rD and rf values correlated negatively with Ki-67 index while D* and rD* value had positive relation with Ki-67 values. ConclusionIVIM MRI is a promising technique for distinguishing different grades of meningiomas. Different subtypes of meningiomas have different IVIM features, which may help to treatment decision and prognosis evaluation.

340P - The study of MIB-1 LI and CD-34 as a marker of proliferative activity and angiogenesis in different grades of meningioma

340P - The study of MIB-1 LI and CD-34 as a marker of proliferative activity and angiogenesis in different grades of meningioma

Impact of 1p/19q codeletion on the diagnosis and prognosis of different grades of meningioma

Background: Meningiomas are one of the most common tumours to affect the central nervous system. Genetic mutations are important in meningeal tumourigenesis, progression and prognosis. In this study, we aimed to examine the effect of 1p/19q deletion on the diagnosis and prognosis of meningioma subtypes using the fluorescence in situ hybridization (FISH) method.Methods: Twenty-four patients with meningioma were retrospectively studied. Tumour samples were obtained from 10 typical, 11 atypical and three anaplastic malignant meningiomas. The most representative tumour sections were screened for 1p/19q deletion using the FISH method.Results: Of the 24 patients, eight were women (33.3%) and 16 (66.7%) were men. The mean age was 56.6 years. The higher-grade meningioma was usually seen in males and had a higher rate of deletion on 1p (p = 0.001). There was a statistically significant difference between the grades and the rate of deletion on 19q (p = 0.042) and between the grades and the rates of polysomy, monosomy and amplification on 19q (p = 0.002; p = 0.001; p = 0.002, respectively). There was no statistical difference between 1p/19q codeletion and the grades of meningioma (p > 0.05). We detected higher level of Ki-67 in the condition of codeletion but did not find a statistical difference (p = 0.0553).Conclusion: Deletion on 1p, as well as deletion, polysomy, monosomy and amplification on 19q, are detected more frequently in high grade meningiomas. This amplification is most likely due to the amplification of oncogenes.

The Study of MIB-1 LI and CD 34 As A Marker of Proliferative Activity and Angiogenesis in Different Grades of Meningioma.

Meningiomas comprise 24-30% of all tumours occurring in the central nervous system. Conventional morphologic critera as studied in routine Haematoxylin and Eosin stained sections (H & E) may not be accurate in grading and assessing prognosis in small stereotactic biopsy specimens. Thus, arises the need for objective methods for assessing tumour biology. Angiogenesis is a key event in the spread of tumours and denotes a poor prognosis. Intratumoural Microvessel Density (MVD) helps in quantification of angiogenesis. To measure the proliferative index by MIB-1 and correlate it with the WHO grading of meningiomas. Also to assess the expression of CD34 in various grades of meningioma and evaluate their angiogenic potential by calculating MVD. Paraffin blocks of 30 surgically resected cases, 10 each of grade I, II and III meningiomas were reviewed. Tumours were graded and subtyped as per WHO criteria. Immunohistochemical staining was done with MIB-1 and CD 34 antibodies. Statistical analysis was performed using Mann - Whitney U test. p-value of < 0.05 was considered significant. The male to female ratio overall was 1:1. The age of the patients ranged from 18-81 years. A 73% of patients had raised intracranial pressure and 18.4% of patients presented with seizures. The mean ± SD MIB-1 LI was 1.14 ± 0.84, 8.94 ± 2.73 and 35.62 ± 4.44 in grade I, II and III tumours respectively which was statistically significant. (p< 0.01). The mean ± SD MVD was 49.67 ± 22.35, 41.37 ± 7.45 and 47.86 ± 10.77 respectively in grade I, II and III tumours (p NS). MIB-1 LI is an important complementary tool to accurately grade meningothelial tumours and assess tumour biology. Specific cycling endothelial markers along with CD 34 & MVD could be used to assess the prognosis of these tumours.

Quantitative proteomic analysis of meningiomas for the identification of surrogate protein markers.

Meningiomas are the most common non-glial tumors of the brain and spine. Pathophysiology and definite histological grading of meningiomas are frequently found to be deceptive due to their unusual morphological features and locations. Here for the first time we report a comprehensive serum proteomic analysis of different grades of meningiomas by using multiple quantitative proteomic and immunoassay-based approaches to obtain mechanistic insights about disease pathogenesis and identify grade specific protein signatures. In silico functional analysis revealed modulation of different vital physiological pathways including complement and coagulation cascades, metabolism of lipids and lipoproteins, immune signaling, cell growth and apoptosis and integrin signaling in meningiomas. ROC curve analysis demonstrated apolipoprotein E and A-I and hemopexin as efficient predictors for meningiomas. Identified proteins like vimentin, alpha-2-macroglobulin, apolipoprotein B and A-I and antithrombin-III, which exhibited a sequential increase in different malignancy grades of meningiomas, could serve as potential predictive markers.

The Role of Microglia and T Cells in Different Grades of Meningioma

The Role of Microglia and T Cells in Different Grades of Meningioma